"Five per cent of respondents said they are using - or previously used - GLP-1 weight-loss drugs like Ozempic, Mounjaro and Wegovy."
"Some 55pc of people said cost was a barrier to use, while 12pc said it wasn't, and a further 33pc said they "don't know"."
Five percent of respondents said they are using or previously used GLP-1 weight-loss drugs such as Ozempic, Mounjaro, and Wegovy. Cost was reported as a barrier by 55% of people. Twelve percent said cost was not a barrier to use. Thirty-three percent said they do not know whether cost would be a barrier. The poll also reflects differing personal experiences among women who reported positive effects from the medication.
Read at Independent
Unable to calculate read time
Collection
[
|
...
]